of the Insights in Hematology

2020 Conference

Alina Tănase, M.D.

Dr. Alina Tanase is head of the afur with expertise in hematology, pediatrics and clinical immunolgy. She was the manager of a postdoctoral research scholarship in a POSDRU 2010-2013 grant entitled “Supporting research by forming highly trained specialists during postdoctoral research”. Dr. Alina Tanase has published several internationally peer-reviewed papers in important journals such as Leukemia, the Lancet Oncology or Transplantation Proceedings.

Ciprian Tomuleasa, M.D.

Dr. Ciprian Tomuleasa is the Congress Director of Insights in Hematology Conference. Dr. Tomuleasa is a young physician-scientiest that is currently affiliated with the Ion Chiricuță Clinical Cancer Center and Iuliu Hațieganu University of Medicine and Pharmacy Cluj Napoca, Romania. He did part of his training as a postdoctoral fellow at the Johns Hopkins University in the department of medicine, division of GI, and his transplant rotations with Dr. Ciurea at the University of Texas MD Anderson Cancer Center. His current research regards the molecular mechanism of haematological malignancies and the translation of his knowledge in the clinical setting. He published 85 papers, was cited 600 times and has a Hirsch index of 16.

Daniela Sauma, Ph.D.

Daniela Sauma has a degree in biochemistry from the University of Chile and obtained her Ph.D. at the Faculty of Sciences of the same University. Her thesis was pioneer work in the field of Immunology by studying the role of Notch signaling pathway in T-cell differentiation. She completed her postdoctoral studies at Fundacion Ciencia & Vida and in 2013 she joined the Department of Biology of the Faculty of Sciences of the University of Chile. Dr. Sauma has directed several undergraduate students and has received several national awards and distinctions including the “For Women in Science Award” of L’ Oreal , UNESCO and CONICYT and Dr. Hermann Niemeyer medal awarded by the Chilean Society for Biochemistry. In 2009 she was recognized as one of the “100 young leaders ” in El Mercurio. Her current research focuses on the study of purinergic signaling in T-cell differentiation.

Francisco Bolanos-Meade, M.D.

Dr. Bolanos-Meade, MD is an oncologist in Baltimore, Maryland. He is currently licensed to practice medicine in Maryland. He is affiliated with Johns Hopkins Hospital and is an Associate Professor of Oncology at Johns Hopkins University School of Medicine.

Gabriel Ghiaur, M.D., Ph.D.

Dr. Ghiaur, a member of the Johns Hopkins Kimmel Cancer Center, is a physician-scientist whose primary interest is normal and malignant hematopoiesis, especially the role of the microenvironment in stem cell biology. His research has translational potential in stem cell therapeutics, as well as acute leukemia.

Gianluca Gaidano, M.D., Ph.D.

Gianluca Gaidano is Professor of Hematology at the Medical School of the University of Eastern Piedmont (Universita’ del Piemonte Orientale), Novara, Italy. He is also the Director of the Division of Hematology of the Academic Hospital “Maggiore della Carità di Novara”, University Vice-Rector for International Affairs, and the Director of the Medical Biotechnologies Master Degree Program at the University of Eastern Piedmont. He is a member of EHA, ASH, ASCO, AACR, Henry Kunkel Society, SIE and SIES, and a former President of the Italian Society of Experimental Hematology. He has been a board member of EHA for years 2015-2019, and is a current board member of the Italian Lymphoma Foundation (FIL), of the Italian Society of Hematology, and of the GIMEMA Working Party on chronic lymphoproliferative disorders. He started his medical career at the University of Turin, where he received his M.D. (1987) and Ph.D (1991), and became a specialist in Internal Medicine and Hematology. From 1990 to 1994, he was at Columbia University (Dalla-Favera’s lab), New York, where he trained in molecular hematology. His research interests relate mainly to the clinical implications of the molecular genetics of lymphoid malignancies, with a particular focus on the development of new diagnostic and prognostic markers as well as targeted treatments for B-cell lymphoma and chronic lymphocytic leukemia (CLL). Using a genomic approach, his research group recently identified several novel genetic alterations predicting poor outcome in CLL. Other fields of interest concern hematologic neoplasias developing in immunodeficient patients. He has contributed to several hematology and oncology textbooks, including the DeVita, Hoffman, and Magrath.

Jo Caers, M.D., Ph.D.

Professor of Hematology
Laboratory of Hematology, University of Liege, Liege, Belgium

Massimo Federico, M.D., Ph.D.

Professor Federico graduated from medical school at Catholic University of Rome and then completed a 3-year hematology post-graduate course at the University of Modena and, after it undertook a 5-year program on internal medicine at the University of Pavia. Professor Federico is board-certified in hematology and internal medicine. After working in the department of internal medicine in Modena, in 1985 he moved to the new area of medical oncology.
Since 1998, Massimo Federico is Professor of Medical Oncology at the University of Modena and Reggio Emilia, Modena, Italy, as well as President of the Angela Serra Association for Cancer Research. From 2011-2013 he was President of Fondazione Italiana Linfomi (FIL). From 2013-2016 chaired the Advisory Bard of the Lymphoma Hub a global online platform whose vision is to provide up-to-date, practical, clinical advice to community hem-oncologists, hematologists and oncologists seeking treatment and management options for Lymphoma and CLL (Lymphomahub.com). He is at present president of the AIBE (Associazione Italo Brasiliana di Ematologia). Currently, Professor Federico is Head of the Oncology Department at Città di Lecce Hospital, Care & Research, in Lecce.

Mihnea Zdrenghea, M.D., Ph.D.

Dr. Mihnea Zdrenghea is one of the most appreciated hematologists in Romania, with a significant backround in both medical and clinical research. Dr. Zdrenghea has completed his PhD in tumor immunology and is the author of more than 20 scientific papers, as well as an author to 6 books. He is an attending physician in hematology at the Oncology Institute “Prof. Dr. Ion Chiricuta” in Cluj-Napoca. The skills and qualification of him as a department leader reflect on the entire research team and it is apparent the the collaboration with partner investigators can be accomplished. The publications and extensive experience in cancer biology research, proven by his ongoing projects and previous results, recommend Dr. Zdrenghea for capably managing a professional team of researchers that have the potential of bringing new innovative results.

Nikolas Kaltz, pHD

Nikolas Kaltz, pHD, is global manager in the marketing department of Miltenyi Biomedicine GmbH and responsible for clinical products for graft engineering in the field of hematology and oncology. He received his academic degree as biologist from the Johannes Gutenberg University in Mainz and the doctorate from the Technical University of Munich in Germany. In 2010 he joined Miltenyi Biotec BV & Co KG and since 2014 has been responsible for the global product management of clinical products in the field of infections and later for graft engineering products. Since December 2019 he continues his work on graft engineering procedures in the marketing department of Miltenyi Biomedicine GmbH.

Ólafur E. Sigurjónsson, M.Sc., Ph.D.

Olafur finished a B.Sc. degree in molecular biology from the faculty of biology, University of Iceland in 1998 and a M.Sc. degree in medical science from the faculty of medicine, University of Iceland in 2001. The topic of his M.Sc. thesis was “Megakaryocyte development in vitro: differentiation, ploidy and apoptosis”. In this thesis, he explored differentiation of megakaryocytes and platelet precursors from heamtopoietic stem cells. In 2002, Olafur started a PhD at the Institute of Immunology and the department of Physiology at the University of Oslo and graduate in 2006. The thesis was titled, “The differentiation potential of somatic stem cells”. In this thesis, Oalfur continued working with hematopoeitic stem cells, further analyzing megakaryocyte development and neural differentiation. Describing new potential stem cells genes (in collaboration with Kristbjörn Orri Guðmundsson and Jonathan R. Keller) as well as describing a potential phenotype for isolation of mesenchymal stem cells from adipose tissue. For this thesis, he was awarded the ” H.M. Kongens gullmedalje” by king Haakon V of Norway in 2007. In 2006 Olafur took over as manager and Principal Investigator at the laboratory of stem cell research and cellular therapy, at the Blood Bank. In 2008 Olafur became assistant professor at the Biomedical Engineering department, School of Science and Engineering, Reykjavik University.

Rahul Bhargava, M.D.

Dr. Rahul Bhargava in 2016 became the first Indian doctor to do and popularize stem cell transplant in multiple sclerosis. His academic journey began with M.D. (Medicine) in the year 2004 followed by DM from one of the most prestigious institutes of the country i.e. AIIMS in the year 2009. However, his unending quest for professional excellence lead him to pursue post DM fellowship in Leukemia & BMT in the year 2010; from Vancouver Hospital, where he was specifically trained in Voluntary Stem Cell transplant & Umbilical cord transplant for various diseases. He has been credited for establishing 6 low cost centres across India namely at Sarvodaya hospital, Batra hospital, Action Balaji hospital etc.. He and his team has done 400+ transplants. He is known for his excellent outcome in stem cell transplant specially in haploidentical transplant and his vision of first integrated centre of excellence in Haematology, paediatric haematology and stem cell transplant has been full filled at FMRI Gurgaon. Dr. Rahul Bhargava has several publications to his credit and in peer – reviewed journals, both nationally & internationally and is an invited speaker at various national and international conferences.

Straciuc Oreste, M.D., Ph.D.

Dr. Straciuc Oreste receiverd his M.D. degree from the University of Medicine and Pharmacy “Victor Babes” Timisoara. He is a doctor in medical sciences, currently being a University Lecturer Dr. at the Faculty of Medicine and Pharmacy of the University of Oradea, and he became a radiology diagnostic doctor in 2003 with proficient in ultrasound, CT, MRI and PET / CT.
He has done several super-specializations, having over 25 years experience in different types of ultrasound (general abdominal-pelvic ultrasound, mammary ultrasound, hip ultrasound in newborns between 6 weeks and 3 months, thyroid ultrasound and laterocervical part ultrasound ), currently being chief physician at the PET / CT Center Pozitron-Diagnosztika Oradea and a primary radiology diagnostician at the GRANDMED Oradea Medical Clinic.

Delia Dima, M.D.

Dr. Delia Dima is a senior hematologist at the Ion Chiricuta Oncology Institute and will talk about the clinical nursing approach for the haemophilia patient, as a symposium organized on behalf of the Romanian Society of Hematology for Romania 3 Project – Strenghten haemophilia care in the north and establish a national registry in Romania, grant awarded for 2020 – 2021 by the Novo Nordisk Haemophilia Foundation.

Tapan Kadia, M.D.

Dr. Tapan Kadia received his M.D. degree from Robert Wood Johnson Medical School in Piscataway, New Jersey. He completed his clinical internship in 2002, clinical residency in 2004, and chief residency in 2005, each at Baylor College of Medicine…
Dr. Kadia is an Associate Professor in the Department of Leukemia at The University of Texas MD Anderson Cancer Center in Houston, Texas. He is actively involved in clinical and translational research for the treatment of patients with leukemia. His particular focus is in developmental therapeutics in acute leukemia, including individualized frontline therapy, biologically rational targeted therapy, and longer term maintenance strategies in AML and ALL. He is primary investigator on numerous trials in acute myeloid leukemia, T-cell leukemias, bone marrow failure states, and is a leader in these. He has received numerous academic and clinical honors and awards for his studies and clinical research. Additionally, he’s authored over 160 peer-reviewed articles, numerous abstracts, and has been invited nationally and internationally for presentation of his research.

Vernon Louw, M.D., Ph.D.

Dr. Vernon Louw is a professor, Head of the Department of Internal Medicine and Clinical Haematologist at the School of Medicine, Faculty of Health Sciences, University of the Free State, South Africa, Chair and Head Clinical Haematology, Department of Medicine, University of Cape Town and a clinical Haematologist in Panorama Mediclinic.
After completing his medical degree (MBChB) and M.Med (Internal Medicine) at the University of Stellenbosch (both cum laude), he spent three years at the Katholieke Universiteit Leuven in Belgium in Clinical Haematology. In 2011, he obtained his Ph.D. in Health Professions Education at the University of the Free State, studying postgraduate education in transfusion medicine. He is the recipient of numerous awards, including the University of Stellenbosch medal for the best postgraduate student of all health-related disciplines in the year 2000. His research focus is in transfusion medicine, education, and HIV-related haematological disease. He has published more than 90 papers in national and international medical journals with more than 250 poster and oral presentations at national, and international meetings. He is a member of, inter alia, the American Society of Hematology (ASH), the International Society of Hematology (ISH), the European Haematology Association (EHA), and the African Society for Blood Transfusion (AfSBT). He serves on the editorial board or as reviewer for a number of national and international medical journals, and is a member of and chairs a number of national and international advisory boards. He has served on the scientific and organizing committees of a number of national and international conferences. His vision is to develop online learning platforms for haematology and transfusion medicine that could benefit healthcare in Africa. Together with his team, he developed the first Anglophone Postgraduate Diploma and Master’s Degree Programmes in Transfusion Medicine in Africa.

Victor Greiff, M.D., Ph. D

Dr. Greiff started his research group in 2018 at the University of Oslo (UiO), Department of Immunology. The group develops computational and experimental tools to decipher, read, predict and re-engineer antibody and T-cell repertoires with the aim to develop fundamentally novel immunodiagnostics, vaccines and immunotherapeutics. He uses his time away from science to catch up on current immunology topics, technology developments, and state of the art algorithms – wait a minute, that’s just more science!

William Wierda, M.D., Ph.D.

William G. Wierda, M.D., Ph.D. is an associate professor of medicine in the Department of Leukemia at The University of Texas M. D. Anderson Cancer Center in Houston, Texas. He received his undergraduate degree in biochemistry at the University of California, Riverside, and his medical degree and Ph.D. in Microbiology and Immunology at the University of Health Sciences/The Chicago Medical School in North Chicago, Illinois. Dr. Wierda completed an internship and residency in Internal Medicine at Duke University Medical Center in Durham, North Carolina, and a subspecialty fellowship in Hematology and Oncology at the University of California, San Diego (UCSD). He has previously served as a clinical instructor at UCSD and a staff physician at the San Diego Veterans Healthcare System. Dr. Wierda took his current position at M.D. Anderson Cancer Center in May 2001.
Dr. Wierda’s research interests are in immunology and immunotherapy strategies for hematologic malignancies. His interest and research is aimed at understanding the immune defects in patients with Chronic Lymphocytic Leukemia (CLL), with a goal directed at correcting these defects and restoring immune function. He has worked on developing vaccine strategies and gene therapy as treatment for patients with CLL. Ultimately, the goal of his research is to incorporate immunotherapy into treatment for patients with CLL. His clinical interest is also in developing frontline and salvage chemoimmunotherapies for patients with CLL.
Dr. Wierda is a member of the American College of Physicians, the American Society of Hematology, American Society of Clinical Oncology, and the American Association of Immunologists. He currently serves as a reviewer for Blood, Cancer, and Leukemia & Lymphoma.

Dr. Anca Bojan

Dr. Anca Bojan is one of the most appreciated hematologists in Romania, with a significant background in both medical and clinical research. Dr. Bojan has completed her PhD on the pathophysiology of multiple myeloma and is the author of more than 20 scientific papers, as well as an author to 6 books. She is an attending physician in hematology at the Oncology Institute “Prof. Dr. Ion Chiricuta” in Cluj-Napoca. Considering her research experience in hematology, both in the clinical and the molecular aspects, Dr. Bojan is a competent professional that can successfully complete the aims of the proposed project.
The skills and qualification of the project leader reflect on the entire research team and it is apparent that the collaboration with partner investigators can be accomplished. The publications and extensive experience in cancer biology research, proven by her ongoing projects and previous results, recommend Dr. Bojan for capably managing a professional team of researchers that have the potential of bringing new and innovative results in Romanian hematology.

Horia Bumbea, M.D., Ph.D.

Horia Bumbea, M.D., Ph.D., is Associate Professor at University of Medicine and Pharmacy Carol Davila at the Department of Hematology in the Emergency University Hospital, Bucharest. He is coordinator of Flowcytometry Lab, and the diagnosis of acute leukemia national program in this center, coordinator of Blood and Marrow Transplant Unit and Center of Expertise in Hematological Rare Disorders, affiliated to ECNM since 2017. Member of European Hematology Association (EHA); European Society of Clinical Cell Analysis (ESCCA); American Society of Hematology (ASH), European LeukemiaNet (ELN), European Research Initiative on CLL (ERIC), member in board of Romanian Society of Hematology and working group of CLL and hematological diagnosis, president of Romanian Association of Cytometry.
Areas of research: clinical studies in hematological malignancies, flowcytometry (immunophenotyping), cellular and molecular diagnostic, targeted immunotherapy, personalized medicine, bone marrow transplant, rare diseases. The experience was accumulated as project manager or responsible partner during the national research projects and clinical trials.

Mihaela Andreescu, M.D.